Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
163 hedge funds and large institutions have $452M invested in Acorda Therapeutics in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 80 increasing their positions, 40 reducing their positions, and 35 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 40
51% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $1.21M
11% less funds holding
Funds holding: 184 → 163 (-21)
41% less capital invested
Capital invested by funds: $763M → $452M (-$311M)
51% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$17.6M |
| 2 |
PA
Perceptive Advisors
New York
|
+$11.5M |
| 3 |
Renaissance Technologies
New York
|
+$5.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.35M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$11.6M |
| 2 |
ClearBridge Investments
New York
|
-$8.06M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.93M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$3.61M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.52M |
ACOR Hedge Fund Activity: Q2 2019 in Review
163 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2019, worth a combined $452M — down 41% from $763M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ACOR and 17 opened new positions — a net loss of 18 holders — while 40 trimmed existing stakes and 80 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $17.6M. The largest seller was Scopia Capital Management, cutting an estimated $11.6M.
- 163 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2019, down from 184 in Q1 2019.
- Funds reported $452M of Acorda Therapeutics stock for Q2 2019, down 41% quarter-over-quarter.
- 17 funds opened new Acorda Therapeutics positions in Q2 2019 and 35 closed out, a net change of -18 holders.
- The largest Acorda Therapeutics buyer in Q2 2019 was Baker Bros. Advisors, an estimated $17.6M added.
- The largest Acorda Therapeutics seller in Q2 2019 was Scopia Capital Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q2 2019.